These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Sept. 18 through Sept. 24, 2025. Source: VerityData

Activist Filings

Staar Surgical $(STAA)$ Yungi Capital disclosed a new position in the eye lens implant maker of 2,500,061 shares. Yungi Capital purchased 2,660,967 shares from Aug. 11 through Sept. 19, 2025, at per share prices ranging from $27.30 to $28.60, but offset those purchases through the sale of 2,572,194 shares from Aug. 5 to Aug. 29 at $26.80 to $27.50. On Aug. 5, Staar Surgical announced its entry into a definitive agreement to be acquired by Alcon in an all-cash deal valued at $1.5 billion, or $28 per share, which represents a significant premium to the stock's closing price prior to the announcement that day. On Sept. 22, Yungi issued an open letter to stockholders, discussing its intent to vote against the proposed merger at the special meeting set to occur on Oct. 23 and citing its belief that the deal "significantly undervalues" the company.

Following the latest activity, Yungi Capital owns an initial 5.1% stake in Staar Surgical's outstanding stock. Shares of Staar Surgical have gained approximately 11.1% in value since the beginning of this year.

Decreases in Holdings

Insight Enterprises(NSIT) ValueAct Capital reduced its stake in the enterprise information-technology company to 2,481,739 shares. ValueAct Capital did so through the sale of 380,000 Insight Enterprises shares from Aug. 18 through Sept. 18, 2025, at per share prices ranging from $119.87 to $133.62.

Following the latest sales, ValueAct Capital continues to own 7.9% of Insight Enterprises' outstanding stock. Shares of Insight Enterprises have lost roughly 23.6% of their value since the beginning of this year.

LENZ Therapeutics (LENZ) Versant Venture Capital VI lowered its stake in the late-stage biopharmaceutical company to 1,183,543 shares. Versant Venture Capital did so through the sale of 323,398 LENZ Therapeutics shares from Aug. 22 through Sept. 18, 2025, at per share prices ranging from $39.01 to $42.23.

Following the latest sales, Versant Venture Capital continues to own 4.1% of LENZ Therapeutics' outstanding stock, placing Versant Venture below the 5% threshold that would require it to report further sales. Shares of LENZ Therapeutics have gained roughly 45.1% in value since the beginning of this year.

Opendoor Technologies(OPEN) Access Industries lowered its stake in the real estate tech platform to 17,638,714 shares. Access Industries did so through the sale of 25,086,200 Opendoor Technologies shares from Sept. 22 through Sept. 23, 2025, at per share prices ranging from $6.98 to $9.29.

Following the latest sales, Access Industries continues to own 2.4% of Opendoor Technologies' outstanding stock, placing Access Industries below the 5% threshold that would require it to report further sales. Shares of Opendoor Technologies have surged 417.6% in value since the beginning of this year.

Email: editors@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

September 26, 2025 17:56 ET (21:56 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.